Table 3 Experimental interventions: study details
Experimental intervention | Data source§ | Study ID# | Study Title | Study acronym |
|---|---|---|---|---|
ABX464 | AIFA website | 2020-001673-75 | A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged ≥ 65 and patients aged ≥18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study). | MiR-AGE |
Acalabrutinib | AIFA website | 2020-001644-25 | A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 | ACE-ID-201 |
ACE inhibitors | AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP |
Acetylsalicyclic acid | AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP |
ClinicalTrials.gov | NCT04808895 | Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19 | Asperum | |
Alteplase | ClinicalTrials.gov | NCT04640194 | A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19 | TRISTARDS |
Anakinra | AIFA website | 2020-001167-93 | A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, and anakinra, an interleukin-1(IL-1) receptor antagonist, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARSCoV-2 infection (Sobi.IMMUNO-101) | Sobi.IMMUNO-101 |
AIFA website | 2020-005828-11 | Supar-guided anakinra treatment for validation of the risk and early management of severe respiratory failure by covid-19: the save-more double-blind, randomized, phase iii confirmatory trial | SAVE-MORE | |
AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP | |
Angiotensin receptor blockers | AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP |
AZD7442 | AIFA website | 2020-005315-44 | A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults | TACKLE Study |
Baricitinib | AIFA website | 2020-001955-42 | BARICIVID-19 STUDY: MultiCentre, randomised, Phase IIa clinical trial evaluating efficacy and tolerability of Baricitinib as add-on treatment of in-patients with COVID-19 compared to standard therapy | BARCIVID |
AIFA website | 2020-001854-23 | Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 | AMMURAVID | |
AIFA website | 2020-001517-21 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection | COV-BARRIER | |
AIFA website | 2020-001185-11 | A proof-of concept study of the use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the treatment of COVID-19-related pneumonia | BREATH trial | |
ClinicalTrials.gov | NCT04358614 | Baricitinib Therapy in COVID-19 | HPrato-4 | |
Bevacizumab | Clincaltrials.gov | NCT04275414 | Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia | BEST-CP |
Canakinumab | AIFA website | 2020-001370-30 | Phase 3 multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID) | CAN-COVID |
AIFA website | 2020-001854-23 | Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 | AMMURAVID | |
Chloroquine | AIFA website | 2020-001366-11 | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | SOLIDARITY |
Cholecalciferol | AIFA website | 2020-002119-23 | COVitaminD Trial: prevenzione di complicanze da COVID-19 in pazienti oncologici in trattamento attivo | COVitaminD |
Clopidogrel | AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP |
Colchicine | AIFA website | 2020-001475-33 | Treatment with COLchicine of patients affected by COLVID-19 : a Pilot Study | COLVID-19 |
AIFA website | 2020-001258-23 | Colchicine To Counteract Inflammatory Response In Covid-19 Pneumonia | ColCOVID | |
AIFA website | 2020-001806-42 | ColcHicine in patients with COVID-19: a home CarE study | CHOICE-19 | |
AIFA website | 2020-002234-32 | Efficacy and Safety of Edoxaban and or Colchicine for patients with SARS-CoV-2 infection managed in the out of hospital setting (COVID 19) | CONVINCE | |
Convalescent plasma | ClinicalTrials.gov | NCT04385043 | Hyperimmune Plasma in Patients With COVID-19 Severe Infection | COV2-CP |
ClinicalTrials.gov | NCT04428021 | Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure | PLACO-COVID | |
ClinicalTrials.gov | NCT04321421 | Hyperimmune Plasma for Critical Patients With COVID-19 | COV19-PLASMA | |
ClinicalTrials.gov | NCT04346589 | Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients | ||
ClinicalTrials.gov | NCT04393727 | Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 | TSUNAMI | |
ClinicalTrials.gov | NCT04418531 | Convalescent Antibodies Infusion in COVID 19 Patients | ||
ClinicalTrials.gov | NCT04374526 | Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. | LIFESAVER | |
ClinicalTrials.gov | NCT04569188 | Convalescent Plasma in COVID-19 Elderly Patients | RESCUE | |
ClinicalTrials.gov | NCT04614012 | Hyperimmune Plasma for Patients With COVID-19 | IMMUNO-COVID19 | |
ClinicalTrials.gov | NCT04622826 | plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients | ||
ClinicalTrials.gov | NCT04721236 | Early Use of Hyperimmune Plasma in COVID-19 | COV-II-PLA | |
ClinicalTrials.gov | NCT04716556 | TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients | ||
COVID-eVax | AIFA website | 2020-003734-20 | A Phase I/Ii Study To Assess The Safety And Immunogenicity Of Covid-Evax, A Candidate Plasmid Dna Vaccine For Covid-19, In Healthy Adult Volunteers | COVID-eVax |
CPI-006 | ClinicalTrials.gov | NCT04734873 | CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients | |
CT-P59 | AIFA website | 2020-003401-60 | A Phase 2/3, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Hospitalized Patients with SARS-CoV-2 Infection | CT-P59 ospedalizzati |
AIFA website | 2020-003369-20 | CT-P59A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection. - CELLTRION | CT-P59 non ospedalizzati | |
Cyclosporin-A | AIFA website | 2020-003505-58 | A proof-of-concept study of the use of Inhaled liposomal -Cyclosporin-A in the treatment of moderate COVID-19-related pneumonia: a two-step phase II clinical trial | INCIPIT |
Dalteparin | AIFA website | 2020-004285-19 | A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 | ACTIVE4 |
Darunavir/cobicistat | AIFA website | 2020-001528-32 | Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study) | ARCO |
DAS181 | ClinicalTrials.gov | NCT04354389 | DAS181 for STOP COVID-19 | |
Defibrotide | AIFA website | 2020-001513-20 | Use of Defibrotide to reduce progression of acute respiratory failure rate in patients with COVID-19 pneumonia | DEF-IVID19 |
Edoxaban | AIFA website | 2020-002234-32 | Efficacy and Safety of Edoxaban and or Colchicine for patients with SARS-CoV-2 infection managed in the out of hospital setting (COVID 19) | CONVINCE |
Emapalumab | AIFA website | 2020-001167-93 | A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, and anakinra, an interleukin-1(IL-1) receptor antagonist, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARSCoV-2 infection (Sobi.IMMUNO-101) | Sobi.IMMUNO-101 |
Enoxaparin | AIFA website | 2020-001708-41 | Enoxaparina for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40mg o.d. versus 40mg b.i.d. A randomized Clinical Trial | X-COVID |
AIFA website | 2020-001972-13 | Randomised controlled trial comparing efficacy and safety of high versus low Low- Molecular Weight Heparin dosages in hospitalised patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD) | COVID-19 HD | |
AIFA website | 2020-001308-40 | Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID19: a pilot phase II single-arm study, INHIXACOVID19 | INHIXACOVID | |
AIFA website | 2020-002214-40 | EMOS-COVID - Enoxaparina | EMOS-COVID | |
AIFA website | 2020-004285-19 | A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 | ACTIVE4 | |
AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP | |
Enoxaparin+Methylprednisolone | AIFA website | 2020-001921-30 | Steroids and unfractionated heparin in critically ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. | STAUNCH |
Favipiravir | AIFA website | 2020-001528-32 | Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study) | ARCO |
AIFA website | 2020-001115-25 | A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Inpatients with COVID-19-General Type (HS216C17 | HS216C17 | |
Fondaparin | AIFA website | 2020-004285-19 | A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 | ACTIVE4 |
GRAd-COV2 | AIFA website | 2020-002835-31 | A Phase 1, Dose-Escalation Study to assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects | RT-CoV-2 |
AIFA website | 2020-005915-39 | A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older. COVITAR | COVITAR | |
Heparin | AIFA website | 2020-004285-19 | A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 | ACTIVE4 |
AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP | |
Heparin+Methylprednisolone | AIFA website | 2020-001921-30 | Steroids and unfractionated heparin in critically ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. | STAUNCH |
Hydroxycloroquine | AIFA website | 2020-001441-39 | Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) | COP-COV |
AIFA website | 2020-001987-28 | PRECOV Idrossiclorochina negli operatori sanitari | PRECOV | |
AIFA website | 2020-001501-24 | PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19) | PROTECT | |
AIFA website | 2020-001558-23 | Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients (Hydro-Stop-COVID19 Trial) | Hydro-Stop | |
AIFA website | 2020-001528-32 | Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study) | ARCO | |
AIFA website | 2020-001366-11 | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | SOLIDARITY | |
Hydroxycloroquine+Azitromycin | AIFA website | 2020-001802-50 | AZI-RCT-COVID-19 - Studio sull'utilizzo di idrossiclorochina+azitromicina | AZI-RCT-COVID-19 |
hzVSF-v13 | AIFA website | 2020-003614-13 | Efficacy and safety of intravenously administered hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled study | hzVSF_v13-0006 |
Interferon beta-1a | AIFA website | 2020-001366-11 | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | SOLIDARITY |
AIFA website | 2020-002458-25 | Randomized, controlled, open label, phase 2 clinical trial of Interferon-β-1a (IFNβ-1a) in COVID-19 patients. | INTERCOP | |
AIFA website | 2020-003872-42 | Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patients | ANTIICIPATE | |
AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP | |
Ivermectin | AIFA website | 2020-002283-32 | Randomized, Double-blind, Multi entre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the early Treatment of COVID-19 | COVER |
Lopinavir/Ritonavir | AIFA website | 2020-001528-32 | Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study) | ARCO |
AIFA website | 2020-001366-11 | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | SOLIDARITY | |
MAD0004J08 | AIFA website | 2020-005469-15 | COVID-19: A Phase I dose-escalation study to evaluate the safty and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody MAD0004j08 in healthy adultse | MAD0004J08 |
Mavrilimumab | AIFA website | 2020-001795-15 | A randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyper-inflammation: the COMBAT-19 trial | COMBAT-19 |
Methyilprednisolone | AIFA website | 2020-001854-23 | Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 | AMMURAVID |
AIFA website | 2020-004323-16 | Uno studio randomizzato multicentrico in doppio cieco per valutare l'efficacia della somministrazione di Metilprednisolone ad alte dosi in aggiunta al trattamento standard in pazienti affetti da polmonite da SARS-CoV2 - Codice: RCT-MP-COVID-19 | RCT-MP-COVID-19 | |
ClinicalTrials.gov | NCT04636671 | Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT) | MEDAS | |
MK-4482 | AIFA website | 2020-003367-26 | A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19 | MK-4482 ospedalizzati |
AIFA website | 2020-003368-24 | “A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Participants ≥18 Years of Age with COVID-19” | MK-4482 non ospedalizzati | |
Nafamostat Mesylate | ClinicalTrials.gov | NCT04352400 | Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) | RACONA |
Opaganib | AIFA website | 2020-002677-95 | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia | ABC-201 |
Oxytocin | ClinicalTrials.gov | NCT04386447 | Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 | OsCOVID19 |
Pamrevlumab | AIFA website | 2020-001472-14 | An Open-Label, Randomized, Parallel-Arm Study Investigating The Efficacy And Safety Of Intravenous Administration Of Pamrevlumab Versus Standard Of Care In Patients With Covid-19 | FibroCov |
Plitidepsin | ClinicalTrials.gov | NCT04784559 | Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection | Neptuno |
Prasugrel | AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP |
ClinicalTrials.gov | NCT04445623 | Prasugrel in Severe COVID-19 Pneumonia | PARTISAN | |
Polyvalent immunoglobulins | AIFA website | 2020-002058-26 | High dose intravenous polyvalent immunoglobulin (IVIG) in patients with early inflammatory COVID-19. | IVIG/H/Covid-19 |
Raloxifene | AIFA website | 2020-003936-25 | Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID- 19 patients. | RLX0120 |
Ravulizumab | AIFA website | 2020-001497-30 | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome | ALXN1210-COV-305 |
Remdesivir | AIFA website | 2020-000842-32 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. (GS-US-540-5774 Study) | GS-US-540-5774 |
AIFA website | 2020-000841-15 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19. (GS-US-540-5773 Study) | GS-US-540-5773 | |
AIFA website | 2020-001366-11 | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | SOLIDARITY | |
AIFA website | 2020-001803-17 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19 (GS-US-540-5823) | GS-US-540-5823 | |
Reparixin | AIFA website | 2020-001645-40 | Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia (REPAVID-19) | REPAVID-19 |
AIFA website | 2020-005919-51 | Studio di fase 3, multicentrico, randomizzato, controllato con placebo, sull'efficacia e la sicurezza di Reparixin nel trattamento di pazienti ospedalizzati con polmonite grave da COVID-19 | REPAVID-19 Phase 3 | |
Ruxolitinib | AIFA website | 2020-001662-11 | Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia (REPAVID-19) | RUXCOVID |
Sarilumab | AIFA website | 2020-001390-76 | ESCAPE Studio di fase 2 sull'utilizzo di sarilumab | ESCAPE |
AIFA website | 2020-001162-12 | An adaptive phase 2/3, randomized, double-blind, placebocontrolled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 (Sarilumab COVID-19). | Sarilumab COVID-19 | |
AIFA website | 2020-001854-23 | Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 | AMMURAVID* | |
AIFA website | 2020-001745-40 | Pilot study on the use of sarilumab in patients with covid-19 infection (COVID-SARI) | COVID-SARI | |
AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP | |
Selinexor | AIFA website | 2020-001411-25 | A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection (XPORT-CoV-1001) | XPORT-CoV-1001 |
Siltuximab | AIFA website | 2020-001854-23 | Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 | AMMURAVID |
Simvastatin | AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP |
Sitagliptin | ClinicalTrials.gov | NCT04365517 | The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients | SIDIACO |
Ticagrelor | AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP |
Tinzaparin | AIFA website | 2020-004285-19 | A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 | ACTIVE4 |
Tirofiban | ClinicalTrials.gov | NCT04368377 | Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 | PIC-19 |
Tocilizumab | AIFA website | 2020-001110-38 | Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19) | TOCIVID-19 |
AIFA website | 2020-001386-37 | RCT-TCZ-COVID-19 somministrazione precoce del Tocilizumab | RCT-TCZ-COVID-19 | |
AIFA website | 2020-001154-22 | A randomized, double-blind, placebocontrolled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe covid-19 pneumonia (Tocilizumab 2020-001154-22) | Tocilizumab 2020-001154-22 | |
AIFA website | 2020-001854-23 | AMMURAVID Studio di fase 3 multiarm della SIMIT | AMMURAVID | |
AIFA website | 2020-005291-35 | A multicenter randomized trial to evaluate the efficacy of tocilizumab in patients with severe Coronavirus Disease 2019 (Covid-19) pneumonia failing glucocorticoids (Anticipant Study) | ANTICIPANT Study | |
AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP | |
ClinicalTrials.gov | NCT04315480 | Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis | ||
Tofacitinib | AIFA website | 2020-002035-30 | TOFAcitinib plus Hydroxycloroquine vs Hydroxycloroquine in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia: a multicenter randomized controlled open label trial | TOFACOV-2 |
ClinicalTrials.gov | NCT04332042 | TOFAcitinib in SARS-CoV2 Pneumonia | TOFACOV | |
Vitamin C | AIFA website | 2015-002340-14 | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | REMAP-CAP |
ClinicalTrials.gov | NCT04323514 | Use of Ascorbic Acid in Patients With COVID 19 |